Sloand, E. M., Olnes, M. J., Shenoy, A., Weinstein, B., Boss, C., Loeliger, K., . . . Young, N. S. (2010). Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions. American Society of Clinical Oncology.
Chicago ZitierstilSloand, Elaine M., et al. Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions. American Society of Clinical Oncology, 2010.
MLA ZitierstilSloand, Elaine M., et al. Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions. American Society of Clinical Oncology, 2010.